ErbB2 expression levels in human tumor cell lines and sensitivity toward NK-92-scFv(FRP5)-ζ cells
| Cell line . | Origin . | No. of ErbB2 receptors* . | Lysis by NK-92 (%)† E/T 10:1 . | Lysis by NK-92-scFv(FRP5)-ζ (%) E/T 10:1 . |
|---|---|---|---|---|
| K562 | Erythroid leukemia | — | 60 | 59 |
| MDA-MB468 | Breast carcinoma | < 5 × 103 | < 10 | < 10 |
| MDA-MB453 | Breast carcinoma | 1 × 106 | < 10 | 91 |
| SKBR3 | Breast carcinoma | 1 × 106 | < 10 | 93 |
| SKOV3 | Ovarian carcinoma | 1 × 105 | < 10 | 68 |
| A431 | Squamous cell carcinoma | 5 × 104 | < 10 | 62 |
| T47D | Breast carcinoma | 3 × 104 | 16 | 74 |
| Cell line . | Origin . | No. of ErbB2 receptors* . | Lysis by NK-92 (%)† E/T 10:1 . | Lysis by NK-92-scFv(FRP5)-ζ (%) E/T 10:1 . |
|---|---|---|---|---|
| K562 | Erythroid leukemia | — | 60 | 59 |
| MDA-MB468 | Breast carcinoma | < 5 × 103 | < 10 | < 10 |
| MDA-MB453 | Breast carcinoma | 1 × 106 | < 10 | 91 |
| SKBR3 | Breast carcinoma | 1 × 106 | < 10 | 93 |
| SKOV3 | Ovarian carcinoma | 1 × 105 | < 10 | 68 |
| A431 | Squamous cell carcinoma | 5 × 104 | < 10 | 62 |
| T47D | Breast carcinoma | 3 × 104 | 16 | 74 |
ErbB2 expression levels for T47D, MDA-MB468,45,46 SKBR3, A431, MDA-MB453,47,48and SKOV3 cells49 were previously reported. Lack of ErbB2 expression in K562 cells was confirmed by immunoblot and FACS analysis (data not shown).
Sensitivity of tumor cells to NK-92 and NK-92-scFv(FRP5)-ζ–mediated lysis was determined in europium release assays after 2 hours of incubation as described in “Materials and methods.” Data are from Figures 2 and 4.